Skip to Main Content

INFORMATION FOR

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment (AHFIRM)

Conditions

Diseases of the Digestive System - Liver

Phase II

What is the purpose of this trial?

This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).

  • Trial with
    DURECT Corporation
  • Start Date
    11/02/2021
  • End Date
    09/30/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/11/2022
  • Study HIC
    #2000030511